300 related articles for article (PubMed ID: 7954054)
1. Assessment of immunocytochemical and histochemical stainings in the distinction between reactive mesothelial cells and adenocarcinoma cells in body effusions.
Chen CJ; Chang SC; Tseng HH
Zhonghua Yi Xue Za Zhi (Taipei); 1994 Sep; 54(3):149-55. PubMed ID: 7954054
[TBL] [Abstract][Full Text] [Related]
2. [A comparative evaluation of immunohistochemical markers for the differential diagnosis between malignant mesothelioma, non-small cell carcinoma involving the pleura, and benign reactive mesothelial cell proliferation].
Szczepulska-Wójcik E; Langfort R; Roszkowski-Sliz K
Pneumonol Alergol Pol; 2007; 75(1):57-69. PubMed ID: 17541913
[TBL] [Abstract][Full Text] [Related]
3. Immunocytochemical panel for distinguishing between carcinoma and reactive mesothelial cells in body cavity fluids.
Politi E; Kandaraki C; Apostolopoulou C; Kyritsi T; Koutselini H
Diagn Cytopathol; 2005 Mar; 32(3):151-5. PubMed ID: 15690338
[TBL] [Abstract][Full Text] [Related]
4. Cytological differential diagnosis among adenocarcinoma, epithelial mesothelioma, and reactive mesothelial cells in serous effusions by immunocytochemistry.
Su XY; Li GD; Liu WP; Xie B; Jiang YH
Diagn Cytopathol; 2011 Dec; 39(12):900-8. PubMed ID: 20836004
[TBL] [Abstract][Full Text] [Related]
5. Malignant mesothelioma: immunohistochemistry and DNA ploidy analysis as methods to differentiate mesothelioma from benign reactive mesothelial cell proliferation and adenocarcinoma in pleural and peritoneal effusions.
Friedman MT; Gentile P; Tarectecan A; Fuchs A
Arch Pathol Lab Med; 1996 Oct; 120(10):959-66. PubMed ID: 12046609
[TBL] [Abstract][Full Text] [Related]
6. Ber-EP4 for differentiating adenocarcinoma from reactive and neoplastic mesothelial cells in serous effusions. Comparison with carcinoembryonic antigen, B72.3 and Leu-M1.
Bailey ME; Brown RW; Mody DR; Cagle P; Ramzy I
Acta Cytol; 1996; 40(6):1212-6. PubMed ID: 8960030
[TBL] [Abstract][Full Text] [Related]
7. Immunophenotyping of mesothelial cells and carcinoma cells with monoclonal antibodies to cytokeratins, vimentin, CEA and EMA improves the cytodiagnosis of serous effusions.
Daste G; Serre G; Mauduyt MA; Vincent C; Caveriviere P; Soleilhavoup JP
Cytopathology; 1991; 2(1):19-28. PubMed ID: 1715202
[TBL] [Abstract][Full Text] [Related]
8. [Comparative study of the expression of CEA and a myelomonocytic antigen (CD15) in serous effusions using two monoclonal antibodies NEO 723 and Leu M1].
Daste G; Berthier F; Mauduyt MA; Soleilhavoup JP
Arch Anat Cytol Pathol; 1992; 40(4):183-9. PubMed ID: 1294046
[TBL] [Abstract][Full Text] [Related]
9. Distinction between cells in serous effusions using a panel of antibodies.
Lauritzen AF
Virchows Arch A Pathol Anat Histopathol; 1987; 411(3):299-304. PubMed ID: 2441518
[TBL] [Abstract][Full Text] [Related]
10. Use of a panel of markers in the differential diagnosis of adenocarcinoma and reactive mesothelial cells in fluid cytology.
Ko EC; Jhala NC; Shultz JJ; Chhieng DC
Am J Clin Pathol; 2001 Nov; 116(5):709-15. PubMed ID: 11710688
[TBL] [Abstract][Full Text] [Related]
11. [The immunocytochemical study of pleural effusion and ascites using Ber-EP-4 antibodies].
Spehn J; Iwanetz S; Schmitz-Huebner U
Dtsch Med Wochenschr; 1995 Sep; 120(36):1197-200. PubMed ID: 7671771
[TBL] [Abstract][Full Text] [Related]
12. The cell adhesion molecule, E-cadherin, distinguishes mesothelial cells from carcinoma cells in fluids.
Schofield K; D'Aquila T; Rimm DL
Cancer; 1997 Oct; 81(5):293-8. PubMed ID: 9349517
[TBL] [Abstract][Full Text] [Related]
13. [Significance of combining detection of E-cadherin, carcinoembryonic antigen, and calretinin in cytological differential diagnosis of serous effusion].
Su XY; Li GD; Liu HB; Jiang LL
Ai Zheng; 2004 Oct; 23(10):1185-9. PubMed ID: 15473932
[TBL] [Abstract][Full Text] [Related]
14. Markers for metastatic adenocarcinoma in serous effusion specimens.
Shield PW; Callan JJ; Devine PL
Diagn Cytopathol; 1994; 11(3):237-45. PubMed ID: 7532566
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic usefulness of EMA, IMP3, and GLUT-1 for the immunocytochemical distinction of malignant cells from reactive mesothelial cells in effusion cytology using cytospin preparations.
Ikeda K; Tate G; Suzuki T; Kitamura T; Mitsuya T
Diagn Cytopathol; 2011 Jun; 39(6):395-401. PubMed ID: 21574259
[TBL] [Abstract][Full Text] [Related]
16. IMP3/L523S, a novel immunocytochemical marker that distinguishes benign and malignant cells: the expression profiles of IMP3/L523S in effusion cytology.
Ikeda K; Tate G; Suzuki T; Kitamura T; Mitsuya T
Hum Pathol; 2010 May; 41(5):745-50. PubMed ID: 20060157
[TBL] [Abstract][Full Text] [Related]
17. [Use of immunohistochemistry in clinical cytology].
Weintraub D; Weintraub J; Vassilakos P
Ann Pathol; 1987; 7(1):25-30. PubMed ID: 3304314
[TBL] [Abstract][Full Text] [Related]
18. Application of Leu M5 (CD 11c) antibody in the cytodiagnosis of body fluids: preliminary results.
Berena J; Sun NC
J Clin Lab Anal; 1993; 7(1):19-25. PubMed ID: 8093902
[TBL] [Abstract][Full Text] [Related]
19. Diagnostic utility of GLUT-1 expression in the cytologic evaluation of serous fluids.
Afify A; Zhou H; Howell L; Paulino AF
Acta Cytol; 2005; 49(6):621-6. PubMed ID: 16450901
[TBL] [Abstract][Full Text] [Related]
20. New diagnostic technique for rapid fluorescence immunocytochemical staining of adenocarcinoma and mesothelial cells using liquid-based cytology.
Morimoto A; Ito A; Hashimoto K; Nakano A; Nagasaka T; Yokoi T
Acta Cytol; 2014; 58(5):461-8. PubMed ID: 25358455
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
